ARTICLE | Clinical News

miRagen reports Phase I data of systemic microRNA therapy in CTCL

October 20, 2017 3:15 PM UTC

miRagen Therapeutics Inc. (NASDAQ:MGEN) reported interim data from 23 evaluable patients with mycosis fungoides-type cutaneous T cell lymphoma (CTCL) in the second part of an open-label, U.S Phase I trial showing that once-weekly 300, 600 and 900 mg doses of systemically administered subcutaneous or IV MRG-106 improved total skin disease in 22 patients (96%). Severity of skin disease was measured by the change from baseline in modified Severity Weighted Assessment Tool (mSWAT) score, which assesses skin disease severity over a patient’s entire body. Additionally, 9 of 13 patients who received MRG-106 for more than 1 month achieved a ≥50% maximal improvement in mSWAT score, and 5 patients maintained a durable response for ≥4 months. MRG-106 was generally well tolerated.

Data were presented at the European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force meeting in London. miRagen said it expects to report longer-term dosing data at the American Society of Hematology meeting in Atlanta in December...

BCIQ Company Profiles

Viridian Therapeutics Inc.

BCIQ Target Profiles

MicroRNA-155 (miR-155)